State Street’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

State Street’s Portfolio KNTE Stock Details KNTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-61,959	Closed	-$147K	–	4420
2023 Q4	$147K	Hold	61,959	–	–	﹤0.01%	3961
2023 Q3	$86.7K	Hold	61,959	–	–	﹤0.01%	4143
2023 Q2	$188K	Sell	61,959 -404,422	-87%	-$1.56M	﹤0.01%	4025
2023 Q1	$2.91M	Buy	466,381 +3,199	+0.7%	+$19.5K	﹤0.01%	3196
2022 Q4	$2.83M	Sell	463,182 -3,339	-0.7%	-$27.2K	﹤0.01%	3268
2022 Q3	$5.58M	Buy	466,521 +14,243	+3%	+$186K	﹤0.01%	3004
2022 Q2	$5.7M	Buy	452,278 +29,124	+7%	+$271K	﹤0.01%	3039
2022 Q1	$4.76M	Buy	423,154 +34,224	+9%	+$377K	﹤0.01%	3207
2021 Q4	$6.89M	Buy	388,930 +56,355	+17%	+$1.19M	﹤0.01%	3097
2021 Q3	$7.66M	Buy	332,575 +95,445	+40%	+$2.08M	﹤0.01%	3023
2021 Q2	$5.52M	Buy	237,130 +53,848	+29%	+$1.37M	﹤0.01%	3191
2021 Q1	$5.71M	Buy	+183,282	New	+$6.39M	﹤0.01%	2995

Other funds holding KNTE

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

FCMV

Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street's KNTE Position: Q1 2024 in Review

State Street sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q1 2024, closing a stake of 61,959 shares — an estimated $147K sold.

State Street first reported a position in KNTE in Q1 2021 and held it in 12 quarters. The position peaked at $7.66M in Q3 2021. 56 funds tracked by Wall St. Rank hold KNTE as of Q1 2024.

State Street reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
State Street sold 61,959 Kinnate Biopharma Inc. Common Stock shares in Q1 2024, an estimated $147K.
State Street first reported a position in Kinnate Biopharma Inc. Common Stock in Q1 2021 and held it in 12 quarters.
State Street's Kinnate Biopharma Inc. Common Stock position peaked at $7.66M in Q3 2021.
56 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q1 2024.

Based on State Street's 13F filing for Q1 2024, filed 15 May 2024.